Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Optimer Pharmaceuticals, a biopharmaceutical company focused on the treatment of Clostridium difficile infection (CDI) and Biocon, a provider of manufacturing services, have entered into a long-term supply agreement for the commercial manufacturing of the active pharmaceutical ingredient Fidaxomicin, Optimer's product candidate for the treatment of CDI.
Subscribe to our email newsletter
Biocon claimed that its expertise in fermentation technology and the team’s prior analytical development work with Fidaxomicin made it a suited manufacturer for Optimer’s product requirements.
Pedro Lichtinger, president and CEO of Optimer, said: “This long-term agreement with Biocon is an important step in establishing a stable supply of Fidaxomicin in the event it is approved.
“For the past five years, Biocon has been an important partner in our Fidaxomicin development program and we look forward to continuing the relationship.”
Kiran Mazumdar Shaw, CMD of Biocon Group, said: “Our partnership with Optimer is an acknowledgement of our manufacturing facilities.
“The close research and development partnership over the last five years has been a learning experience for all the Biocon staffers working on this project.”